BioMarin Pharmaceuticals
BMRN
BMRN
541 hedge funds and large institutions have $14.7B invested in BioMarin Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 193 increasing their positions, 193 reducing their positions, and 70 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
7% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 70
10% less call options, than puts
Call options by funds: $85.1M | Put options by funds: $94.2M
3% less funds holding
Funds holding: 559 → 541 (-18)
Holders
541
Holding in Top 10
12
Calls
$85.1M
Puts
$94.2M
Top Buyers
| 1 | +$159M | |
| 2 | +$104M | |
| 3 | +$67.7M | |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$55.9M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$52.1M |
Top Sellers
| 1 | -$355M | |
| 2 | -$84.8M | |
| 3 | -$78.4M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$74.6M |
| 5 |
MNG
Manning & Napier Group
Fairport,
New York
|
-$60.4M |